CYP11B2

Across TCGA pan-cancer cohorts, CYP11B2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP11B2 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CYP11B2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYP11B2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and STAD show a favorable association.

LIHC, SKCM, and LUAD are the cancer types where CYP11B2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.092	0.716	<.001	21	view →
SKCM	DFS	Median	III,IV	0.876	0.238	.008	11	view →
LUAD	DFS	Median	All	0.099	0.369	.016	7	view →
SCLC	OS	Median	III,IV	0.205	0.650	.009	6	view →
STAD	DFS	Median	IV	1.000	0.284	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP11B2–LIHC (OS)

Open the LIHC breakdown →